Effects of CYP2C9 polymorphism on the pharmacokinetics of irbesartan in healthy Korean subjects

被引：0
|
作者：
Kim, Mi-Jung
Bae, Jung -Woo
Han, Ho-Kyun
Choi, Sun-Ok
Kim, Ok-Hee
Jang, Choon-Gon
Lee, Jin-Hee
Kim, Nam-Tae
Lee, Seok-Yong
机构：
[1] Sungkyunkwan Univ, Coll Pharm, Seoul, South Korea
[2] Natl Inst Toxicol Res, Seoul, South Korea
来源：
ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷
关键词：
Irbesartan; CYP2C9; polymorphism; pharmacokinetics;
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
引用
收藏
页码：231 / 231
页数：1
相关论文
共 50 条
  • [41] In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
    Jin, Yi
    Borell, Hubert
    Gardin, Anne
    Ufer, Mike
    Huth, Felix
    Camenisch, Gian
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 74 (04) : 455 - 464
  • [42] Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
    Anne Gardin
    Kasra Shakeri-Nejad
    Andrea Feller
    Felix Huth
    Srikanth Neelakantham
    Swati Dumitras
    European Journal of Clinical Pharmacology, 2019, 75 : 1565 - 1574
  • [43] Effect of CYP2C9*3 mutant variants on meloxicam pharmacokinetics in a healthy Chinese population
    Zhang, M.
    Yang, Y.
    Zhao, G.
    Di, X.
    Xu, L.
    Jiang, N.
    Xu, J.
    Xu, X.
    GENETICS AND MOLECULAR RESEARCH, 2014, 13 (01) : 831 - 837
  • [44] Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes
    Gardin, Anne
    Shakeri-Nejad, Kasra
    Feller, Andrea
    Huth, Felix
    Neelakantham, Srikanth
    Dumitras, Swati
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 75 (11) : 1565 - 1574
  • [45] Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects
    Zhang, Dan
    Wang, Xiaolin
    Yang, Man
    Wang, Guocai
    Liu, Huichen
    XENOBIOTICA, 2011, 41 (06) : 511 - 517
  • [46] The Effect of UGT 1A9, CYP2B6 and CYP2C9 Genes Polymorphism on Propofol Pharmacokinetics in Children
    Pavlovic, Dimitrije
    Budic, Ivana
    Stoimenov, Tatjana Jevtovic
    Stokanovic, Dragana
    Marjanovic, Vesna
    Stevic, Marija
    Slavkovic, Milan
    Simic, Dusica
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2020, 13 : 13 - 27
  • [47] The effect of bucolome, a CYP2C9 inhibitor, on the pharmacokinetics of losartan
    Kobayashi, Mariko
    Takagi, Miho
    Fukumoto, Kyoko
    Kato, Ryuji
    Tanaka, Kazuhiko
    Ueno, Kazuyuki
    DRUG METABOLISM AND PHARMACOKINETICS, 2008, 23 (02) : 115 - 119
  • [48] Genetic analysis of CYP2C9 polymorphism in a Japanese population
    Nasu, K
    Kubota, T
    Ishizaki, T
    PHARMACOGENETICS, 1997, 7 (05): : 405 - 409
  • [49] Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients
    Sukhyang Lee
    Jae-Moon Kim
    Chin-Sang Chung
    Kyoung Joo Cho
    Jeong Hee Kim
    Archives of Pharmacal Research, 2003, 26 : 967 - 972
  • [50] Polymorphism in CYP2C9 as a non-critical factor of warfarin dosage adjustment in Korean patients
    Lee, S
    Kim, JM
    Chung, CS
    Cho, KJ
    Kim, JH
    ARCHIVES OF PHARMACAL RESEARCH, 2003, 26 (11) : 967 - 972
12345